David Drutz is Director of Altimmune, Inc.. Currently has a direct ownership of 20,151 shares of ALT, which is worth approximately $135,817. The most recent transaction as insider was on Nov 18, 2022, when has been sold 139 shares (Common Stock, par value $0.0001) at a price of $2.4 per share, resulting in proceeds of $333. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 20.2K
0% 3M change
0% 12M change
Total Value Held $135,817

David Drutz Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 18 2022
BUY
Exercise of conversion of derivative security
$333 $2.4 p/Share
139 Added 0.69%
20,151 Common Stock, par valu...
Jun 15 2022
BUY
Open market or private purchase
$8,000 $8.0 p/Share
1,000 Added 4.76%
20,012 Common Stock, par valu...
May 24 2022
BUY
Open market or private purchase
$5,400 $4.5 p/Share
1,200 Added 5.94%
19,012 Common Stock, par valu...
Jan 25 2022
BUY
Exercise of conversion of derivative security
$168 $2.4 p/Share
70 Added 0.39%
17,882 Common Stock, par valu...
Dec 14 2021
BUY
Exercise of conversion of derivative security
$334 $2.4 p/Share
139 Added 0.77%
17,812 Common Stock, par valu...
Nov 19 2021
BUY
Exercise of conversion of derivative security
$168 $2.4 p/Share
70 Added 0.39%
17,673 Common Stock, par valu...
Nov 13 2020
BUY
Exercise of conversion of derivative security
$144 $2.4 p/Share
60 Added 0.34%
17,603 Common Stock, par valu...
Sep 24 2020
BUY
Exercise of conversion of derivative security
-
16,850 Added 48.99%
17,543 Common Stock, par valu...
DD

David Drutz

Director
Gaithersburg, MD

Track Institutional and Insider Activities on ALT

Follow Altimmune, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALT shares.

Notify only if

Insider Trading

Get notified when an Altimmune, Inc. insider buys or sells ALT shares.

Notify only if

News

Receive news related to Altimmune, Inc.

Track Activities on ALT